A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review

in Cancer Molecular Targets and Therapeutics

• Kai Sun
• Peng Wang

Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p

in Cancer Molecular Targets and Therapeutics

• Guodong Huang
• Yuxia Liu
• Lisha Li
• Bing Li
• Ting Jiang
• Yufeng Cao
• Xiaoping Yang
• Xinning Liu
• Honglin Qu
• Shitao Li

Unraveling IFI44L’s biofunction in human disease

in Cancer Molecular Targets and Therapeutics

• Juan Du
• Hui Luo
• Shuang Ye
• Hui Zhang
• Zhen Zheng
• Kaitai Liu

Hyaluronic acid–targeted topotecan liposomes improve therapeutic efficacy against lung cancer in animals

in Cancer Molecular Targets and Therapeutics

• Gangqiang Xue
• Lu Tang
• Xinyan Pan
• Sanni Li
• Juan Zhao

Research progress and treatment status of Malignant Ascites

in Cancer Molecular Targets and Therapeutics

ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target

in Cancer Molecular Targets and Therapeutics

• Tonglin Sun
• Xi Li
• Yi Zhang
• Bingwen Zou
• Yan Zhang

Molecular glue degrader for tumor treatment

in Cancer Molecular Targets and Therapeutics

• Yuhan Hu
• Yan Yan
• Jiehao Wang
• Jiangxue Hou
• Quande Lin

Corrigendum: Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance

in Cancer Molecular Targets and Therapeutics

• Fatemeh Yazarlou
• Ivan Martinez
• Leonard Lipovich

Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11

in Cancer Molecular Targets and Therapeutics

• Vid Mlakar
• Ina Oehme
• Laurence Lesne
• Sara Najafi
• Marc Ansari
• Fabienne Gumy-Pause

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions

in Cancer Molecular Targets and Therapeutics

• Jianhua Ding
• Chaihong Yeong

Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy

in Cancer Molecular Targets and Therapeutics

• Emile Youssef
• Shuai Zhao
• Connor Purcell
• Gary L. Olson
• Wafik S. El-Deiry

The role of N6-methyladenosine modification in tumor angiogenesis

in Cancer Molecular Targets and Therapeutics

• Lifei Qin
• Xinya Zeng
• Xinze Qiu
• Xingmei Chen
• Shiquan Liu

Metabolomics and network pharmacology–guided analysis of TNF-α expression by Argemone mexicana (Linn) targeting NF-kB the signalling pathway in cancer cell lines

in Cancer Molecular Targets and Therapeutics

• Sunanda Kulshrestha
• Anjana Goel
• Subhadip Banerjee
• Rohit Sharma
• Mohammad Rashid Khan
• Kow-Tong Chen

Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight

in Cancer Molecular Targets and Therapeutics

• Kemin Sun
• Ye Shen
• Xiang Xiao
• Hao Xu
• Quanli Zhang
• Ming Li

Circular RNA CDR1as/ciRS-7– a novel biomarker in solid tumors

in Cancer Molecular Targets and Therapeutics

• Yun Zhang
• Chanyu Xiong
• Zhilin Jiang
• Xiao Wang
• Juanjuan Ji
• Yan Pan
• Tianshu Yu
• Zihao Wang
• Lin Zhu
• Yumei Yue

The role of ATP6V0D2 in breast cancer: associations with prognosis, immune characteristics, and TNBC progression

in Cancer Molecular Targets and Therapeutics

• Jingyu Zhang
• Lixian Yang
• Bin Xu
• Haibo Ji
• Shuo Liu
• Xiaohan Wang
• Xiaolong Li
• Quanle Wang
• Zhenchuan Song